Sihuan Pharmaceutical Holdings Group Ltd. (0460.HK)

Sihuan Pharmaceutical Holdings Group Ltd. (0460.HK) — VMCI valuation read

Headline read on 0460.HK: VMCI of 40/100 versus a Healthcare sector median of 50. The 10-point below-median position is what makes Sihuan Pharmaceutical Holdings Group Ltd. a relative-value laggard in the mid-cap cohort, before any pillar-level review.

Form 4 filings on 0460.HK: zero in the trailing 30 days. The absence of insider transactions is itself a data point, just a low-information one. The thesis runs on financials and price action until that changes.

**Investor frame.** Three reads on 0460.HK: value (0460.HK trades at 25.0x earnings, 39% above the Healthcare median of 18.0x), quality (ROIC of 15.0% sits 5.0pp above the Healthcare median (10.0%)), and risk (net debt to EBITDA of -1.6x leaves covenant headroom). The value read also implies an EV/EBITDA gap of +4.0x against the Healthcare 12.0x baseline.

0460.HK fell 1.1% over the trailing 7 days, with a +0.6% read on a 30-day basis.